ClinicalTrials.gg
RecruitingNCT06258109LONG-RECAPUpdated Dec 13, 2024

Risk of Recurrent CeAD After Pregnancy

An observational study in Cervical Artery Dissection and Pregnancy Complications, sponsored by University Hospital, Basel, Switzerland. Recruiting at 12 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by University Hospital, Basel, Switzerland · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Pregnancy Complications with a site in United States — 39 open to participants now, 47 under way, 1 of them phase 3. Pregnancy Complications · United States.

Planned enrollment
17th of 61
1,000 · median 477
Started
2023
with 9 others
Observational
61 of 127
20 open now
Primary completion
2024-12
later than 1 of 46 live
Registered
93rd of 127
by date

Among the 127 studies in Pregnancy Complications with a site in United States, this one is the 17th largest by planned enrollment of the 61 observational ones that give a count, is one of 10 that started in 2023, is one of 61 observational ones, reaches primary completion later than 1 of the 46 other live ones, and was the 93rd registered.

Pregnancy Complications

411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.

Browse Pregnancy Complications studies →

Open to participants now

39 of the 127 studies in Pregnancy Complications with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pregnancy Complications studies recruiting now, 43 (48%) set no upper age limit and 44 (49%) stop at 75 or younger; 22 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Pregnancy Complications with a site in United States, or all of them as a file.
02

Study summary

Primary objective: To determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data.

Methods: Multicentric, observational case-control study based on pooled individual patient data from several stroke centers.

Primary endpoint: Primary composite outcome measure includes the following outcomes: (i) occurrence of recurrent CeAD, (ii) occurrence of ischemic or hemorrhagic stroke, (iii) death.

Read the detailed description

Background: Cervical artery dissection (CeAD) is a leading cause of stroke in women of childbearing age. Among the population with an initial CeAD, about 9% show a recurrence event (a range from 0 to 25% has been reported). Recurrence of CeAD can occur for several years after the initial event. CeAD has been shown to occur in association with pregnancy, and the postpartum period, yet it remains unclear whether pregnancy increases the risk of recurrence or delayed stroke. Previous studies on this subject are either based on small sample sizes or lack long-term data.

Objective: The investigators want to determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data.

Furthermore, it will be investigated whether the mode of delivery affects recurrence and if dissections occurred during a particular phase of a woman's reproductive process. The investigators will also investigate if women actively decided against another pregnancy due to the initial CeAD.

Methods: This study will be a multicenter, exploratory case-control study using pooled individual patient data from several stroke centers. The data will be obtained through review of medical records and patient interviews. The study will include all women with any prior CeAD who have had long-term follow-up (at least 6 months, with no upper limit), including information about pregnancy and recurrence of CeAD.

Primary endpoint is a composite outcome measure which consists of (i) occurrence of recurrent CeAD, (ii) occurrence of ischemic or hemorrhagic stroke, (iii) death. Secondary endpoints are the individual components of the primary endpoint and functional outcome assessed by the modified Ranking scale.

Statistical analysis will be used to determine the odds of the primary and secondary endpoints in women who had subsequent pregnancies compared to those who did not.

03

Conditions studied

  • Cervical Artery Dissection
  • Pregnancy Complications

Keywords

  • Ischemic Stroke
  • Hemorrhagic Stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Female patients aged ≥18 years with prior CeAD.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female
  • prior symptomatic cervical artery dissection (= index CeAD)
  • at least one long-term follow-up visit (at least 6 months after the initial event)
  • with information available on outcome events:
  • recurrent dissection
  • ischemic stroke
  • hemorrhagic stroke
  • functional outcome assessed by mRS score
  • with data on pregnancy after the initial event
  • at least 18 years old at the initial event

Exclusion criteria

Exclusion Criteria:

  • Male patients
  • Age \<18 years
  • No long-term follow-up available or long-term follow-up \< 6 months after initial event
  • No data on pregnancy after initial event available
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Women with pregnancy after index CeAD

    Women who became pregnant at least once after first index CeAD

  • Women without pregnancy after index CeAD

    Women who did not became pregnant after first index CeAD

06

What researchers measure

Primary outcomes

  1. Number of participants with composite outcome measure - recurrent CeAD, ischemic stroke, hemorrhagic stroke and/or death

    The composite outcome measure includes the following outcome measures during the follow-up: (i) occurence of recurrent cervical artery dissection (CeAD), (ii) occurrence of any ischemic stroke, (iii) occurrence of any hemorrhagic stroke, (iv) death.

    Time frame: From date of first CeAD until date of latest follow-up assessed up to 35 years

Secondary outcomes

  1. Number of participants with recurrent cervical artery dissection

    assessed by medical history or clinical suspicion with confirmation by cerebrovascular imaging (MRI, MRI angiography, CT, CT angiography, digital subtraction angiography and/or ultrasound)

    Time frame: From date of first CeAD until date of latest follow-up assessed up to 35 years

  2. Number of participants with new ischemic stroke

    assessed by medical history or clinical suspicion with confirmation by cerebrovascular imaging (MRI and/or CT)

    Time frame: From date of first CeAD until date of latest follow-up assessed up to 35 years

  3. Number of participants with new hemorrhagic stroke

    Intracerebral hemorrhage or subarachnoid hemorrhage assessed by medical history or clinical suspicion with confirmation by cerebrovascular imaging (MRI and/or CT)

    Time frame: From date of first CeAD until date of latest follow-up assessed up to 35 years

  4. Number of participants with death

    Time frame: From date of first CeAD until date of latest follow-up assessed up to 35 years

  5. Functional outcome as assessed by modified Rankin Scale (mRS)

    The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. 1. - No significant disability. Able to carry out all usual activities, despite some symptoms. 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. - Moderate disability. Requires some help, but able to walk unassisted. 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. - Dead.

    Time frame: At date of latest, individual follow-up assessed up to 35 years after first CeAD

07

Study locations

12 of 12 sites recruiting
  • University of Utah
    Salt Lake City, Utah 84112, United States
    Recruiting
  • University of Virginia
    Charlottesville, Virginia 22908, United States
    Recruiting
  • Stroke Unit Sanatorio Allende
    Córdoba, X5000BFB, Argentina
    Recruiting
  • Department of Neurology, Medical University of Innsbruck
    Innsbruck, Tirol 6020, Austria
    Recruiting
  • Helsinki University Central Hospital
    Helsinki, Finland
    Recruiting
  • Charité Universitätsmedizin, Centrum für Schlaganfallforschung
    Berlin, 10117, Germany
    Recruiting
  • Neurologische Klinik und Poliklinik, LMU Klinikum Campus Großhadern
    Munich, 81377, Germany
    Recruiting
  • Hadassah-Hebrew University Medical Center
    Jerusalem, 91120, Israel
    Recruiting
  • Neurology Clinic, University of Brescia
    Brescia, Italy
    Recruiting
  • Stroke Clinic, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez
    Mexico City, 14269, Mexico
    Recruiting
  • University Hospital Basel, Stroke Center
    Basel, 4031, Switzerland
    Recruiting
  • University Hospital Zurich, Stroke Center
    Zurich, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Dec 2024, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2024
First posted
Feb 14, 2024
StartActual
Jan 1, 2023
Primary completionActual
Dec 1, 2024
CompletionEst.
Jul 1, 2025
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06258109
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Jan 1, 2023
Primary completion
Dec 1, 2024
Completion
Jul 1, 2025 (estimated)
Last update
Dec 13, 2024

Study contacts

Stefan T Engelter, MD
Contact
stefan.engelter@felixplatter.ch
+41 61 326 41 05
Sandro K Fischer
Contact
sandrokevin.fischer@usb.ch
+41 61 328 47 84
Stefan T Engelter, MD
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion